Press releases
- Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4:30 p.m. Eastern Time.
- Dexcom Expands AID Partnership Into The Netherlands
- Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes
- Dexcom G7 Now Connects Directly to Apple Watch in the U.S.
- Dexcom Wins Access to Dexcom ONE for 100,000 People Living With Type 2 Diabetes
- Nova Scotia Now Providing Coverage for Dexcom Continuous Glucose Monitoring Systems
- Dexcom Announces Upcoming Conference Presentation
- Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM
- Dexcom Launches Innovative New Sensor as Groundbreaking Report Reveals Alarming Rates of Anxiety and Depression in Those With Type 2 Diabetes
- Dexcom Reports First Quarter 2024 Financial Results
More ▼
Key statistics
As of last trade Dexcom Inc (0A4M:LSE) traded at 110.68, -22.04% below its 52-week high of 141.97, set on Apr 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 110.68 |
Average volume | 1.63k |
---|---|
Shares outstanding | 397.68m |
Free float | 396.46m |
P/E (TTM) | 75.54 |
Market cap | 45.58bn USD |
EPS (TTM) | 1.52 USD |
Data delayed at least 20 minutes, as of Jul 19 2024 18:43 BST.
More ▼